Literature DB >> 17707267

Transperineal injection of hyaluronic acid in anterior perirectal fat to decrease rectal toxicity from radiation delivered with intensity modulated brachytherapy or EBRT for prostate cancer patients.

Pedro J Prada1, José Fernández, Alvaro A Martinez, Angeles de la Rúa, Jose M Gonzalez, Jose M Fernandez, German Juan.   

Abstract

PURPOSE: Rectal toxicity remains a serious complication affecting quality of life for prostate cancer patients treated with radiotherapy. We began an investigational trial injecting hyaluronic acid (HA) in the perirectal fat to increase the distance between the prostate and the anterior rectal wall. This is the first report using HA injection in oncology. METHODS AND MATERIALS: This is a trial of external beam radiation therapy with HDR brachytherapy boosts in prostate cancer. During the two high-dose-rate (HDR) fractions, thermoluminescent dosimeter dosimeters were placed in the urethra and in the rectum. Before the second HDR fraction, 3-7 mL (mean, 6 mL) of HA was injected under transrectal ultrasound guidance in the perirectal fat to systematically create a 1.5-cm space. Urethral and rectal HDR doses were calculated and measured. Computed tomography and magnetic resonance imaging were used to assess the stability of the new space.
RESULTS: Twenty-seven patients enrolled in the study. No toxicity was produced from the HA or the injection. In follow-up computed tomography and magnetic resonance imaging, the HA injection did not migrate or change in mass/shape for close to 1 year. The mean distance between rectum and prostate was 2.0 cm along the entire length of the prostate. The median measured rectal dose, when normalized to the median urethral dose, demonstrated a decrease in dose from 47.1% to 39.2% (p < 0.001) with or without injection. For an HDR boost dose of 1150 cGy, the rectum mean Dmax reduction was from 708 cGy to 507 cGy, p < 0.001, and the rectum mean Dmean drop was from 608 to 442 cGy, p < 0.001 post-HA injection.
CONCLUSION: The new 2-cm distance derived from the HA injection significantly decreased rectal dose in HDR brachytherapy. Because of the several-month duration of stability, the same distance was maintained during the course of external beam radiation therapy.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17707267     DOI: 10.1016/j.ijrobp.2007.02.034

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  46 in total

1.  Current role of spacers for prostate cancer radiotherapy.

Authors:  Michael Pinkawa
Journal:  World J Clin Oncol       Date:  2015-12-10

2.  Favorable outcome of intraoperative radiotherapy to the primary site in patients with metastatic prostate cancer.

Authors:  Toshihiro Kanda; Syohei Fukuda; Naotaka Fukui; Yu Ohkubo; Tomoko Kazumoto; Yoshihiro Saito; Ayataka Ishikawa; Masafumi Kurosumi; Yukio Kageyama; Yasuhisa Fujii; Kazunori Kihara
Journal:  Int J Clin Oncol       Date:  2016-01-11       Impact factor: 3.402

Review 3.  A review of rectal toxicity following permanent low dose-rate prostate brachytherapy and the potential value of biodegradable rectal spacers.

Authors:  M E Schutzer; P F Orio; M C Biagioli; D A Asher; H Lomas; D Moghanaki
Journal:  Prostate Cancer Prostatic Dis       Date:  2015-02-17       Impact factor: 5.554

4.  Efficacy of a rectal spacer with prostate SABR-first UK experience.

Authors:  Raymond B King; Sarah Os Osman; Ciaran Fairmichael; Denise M Irvine; Ciara A Lyons; Ananth Ravi; Joe M O'Sullivan; Alan R Hounsell; Darren M Mitchell; Conor K McGarry; Suneil Jain
Journal:  Br J Radiol       Date:  2018-01-23       Impact factor: 3.039

5.  Treatment planning after hydrogel injection during radiotherapy of prostate cancer.

Authors:  M Pinkawa; C Bornemann; N Escobar-Corral; M D Piroth; R Holy; M J Eble
Journal:  Strahlenther Onkol       Date:  2013-07-10       Impact factor: 3.621

6.  PEG spacer gel and adaptive planning vs single plan in external prostate radiotherapy--clinical dosimetry evaluation.

Authors:  Vesa-Pekka Heikkilä
Journal:  Br J Radiol       Date:  2015-09-15       Impact factor: 3.039

7.  A multi-institutional clinical trial of rectal dose reduction via injected polyethylene-glycol hydrogel during intensity modulated radiation therapy for prostate cancer: analysis of dosimetric outcomes.

Authors:  Danny Y Song; Klaus K Herfarth; Matthias Uhl; Michael J Eble; Michael Pinkawa; Baukelien van Triest; Robin Kalisvaart; Damien C Weber; Raymond Miralbell; Theodore L Deweese; Eric C Ford
Journal:  Int J Radiat Oncol Biol Phys       Date:  2013-02-13       Impact factor: 7.038

8.  Effects of prostate-rectum separation on rectal dose from external beam radiotherapy.

Authors:  Robert C Susil; Todd R McNutt; Theodore L DeWeese; Danny Song
Journal:  Int J Radiat Oncol Biol Phys       Date:  2009-11-24       Impact factor: 7.038

Review 9.  Reducing rectal injury during external beam radiotherapy for prostate cancer.

Authors:  Riccardo Valdagni; Tiziana Rancati
Journal:  Nat Rev Urol       Date:  2013-05-14       Impact factor: 14.432

10.  High-dose-rate intensity modulated brachytherapy with external-beam radiotherapy improves local and biochemical control in patients with high-risk prostate cancer.

Authors:  P J Prada; H González; J Fernández; P Bilbao
Journal:  Clin Transl Oncol       Date:  2008-07       Impact factor: 3.405

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.